Onesource Specialty Pharma
- P/E
- Not meaningful: loss-making over the last twelve months
Key Fundamentals
SmallcapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 0.59%
- Debt to Equity
- 0.22
- EPS (TTM)
- −₹4.24
- Book Value
- ₹516.32
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- 3.07
- ROE
- −1.09%
- Dividend Yield
- 0.00%
- EBITDA
- ₹319 Cr
- 52W High
- ₹1,917.80
- 52W Low
- ₹1,057.00
- Day Range
- ₹1,566.00 – ₹1,599.80
- Volume
- 4,81,453
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Onesource Specialty Pharma (this company) | ₹1,583.60 | — | ₹18,106 Cr | 3.07 | 0.00% | −1.09% | 0.59% | ₹1,543 Cr | −₹49 Cr |
| Median 8 companies | ₹1,678.50 | 38.81 | ₹1,25,337 Cr | 4.57 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 93/100
Category scores
- Quality
- 18
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 24
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 22
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 25
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 29
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 68
- Strong
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
5- Stock is trading at 2.70 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.63% over last 3 years.
- Promoters have pledged 37.2% of their holding.
- Company has high debtors of 177 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 3 | 4 | 12 |
| Oscillators | Bullish | 2 | 4 | 3 |
| Moving Averages | Strong Bullish | 1 | 0 | 9 |
Oscillators
Bullish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 60.24
- Neutral
- MACD (12,26,9)
- 13.25
- Bullish
- SMA (50)
- 1,523.24
- Bullish
- SMA (200)
- 1,549.53
- Bullish
As of
Analyst Rating
4 of 4 analysts rate Buy, 0 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 5Y | +132.35% |
|---|---|
| 3Y | +231.60% |
| 1Y | −1.59% |
| TTM | +4.26% |
Net profit
| 5Y | Loss narrowed by ₹47 Cr |
|---|---|
| 3Y | Loss narrowed by ₹726 Cr |
| 1Y | Loss widened by ₹56 Cr |
| TTM | Loss widened by ₹36 Cr |
Operating cash flow
| 5Y | Turned positive |
|---|---|
| 3Y | Turned positive |
| 1Y | Turned positive |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | +359.48 pp |
|---|---|
| 3Y | +434.20 pp |
| 1Y | −10.94 pp |
| TTM | −11.20 pp |
Revenue by year
| Mar 2021 | ₹21.00 Cr |
|---|---|
| Mar 2022 | ₹132 Cr |
| Mar 2023 | ₹39.00 Cr |
| Mar 2024 | ₹172 Cr |
| Mar 2025 | ₹1,445 Cr |
| Mar 2026 | ₹1,422 Cr |
Net profit by year
| Mar 2021 | −₹121 Cr |
|---|---|
| Mar 2022 | −₹231 Cr |
| Mar 2023 | −₹800 Cr |
| Mar 2024 | −₹391 Cr |
| Mar 2025 | −₹18.00 Cr |
| Mar 2026 | −₹74.00 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
OneSource Specialty Pharma Ltd trades at ₹1,568.7 with a market cap of ₹17,946 crore as of 2026-11-03. The company has delivered exceptional compounded sales growth of 232% over three years but has turned unprofitable on a TTM basis with an EPS of -₹4.24 and negative ROE of -1.27%, presenting a mixed picture of rapid revenue scaling alongside persistent profitability challenges.
- Compounded sales growth of 232% over three years reflects a sharp revenue ramp-up, indicating strong demand traction in the specialty pharma segment
- Five-year compounded sales growth of 131% demonstrates sustained long-term revenue momentum, not just a one-off spike
- Debt-to-equity ratio of 0.22 is relatively conservative, suggesting the balance sheet is not overleveraged despite rapid expansion
- Compounded profit growth of 24% over three years shows that the company has historically been able to translate revenue growth into earnings growth over medium-term horizons
- Five-year compounded profit growth of 8% indicates the company has maintained positive earnings trajectory over longer periods despite recent TTM losses
- The stock is trading 18.2% below its 52-week high of ₹1,917.8, which may reflect a correction from elevated levels rather than a structural deterioration
- The stock has risen 48.4% from its 52-week low of ₹1,057, indicating buyer interest at lower levels and a recovery trend from the bottom
- TTM compounded profit growth of -142% signals a severe deterioration in profitability, with the company swinging into losses on a trailing basis
- TTM EPS of -₹4.24 confirms the company is currently loss-making, making valuation on a P/E basis not meaningful
- Promoters have pledged 37.2% of their holding, creating risk of forced selling in adverse market conditions and raising governance concerns
- Debtor days stand at 177, indicating very slow collections that strain working capital and raise questions about the quality of revenue
- Three-year average ROE of -3% and last-year ROE of -1% show the company has consistently failed to generate positive returns on shareholder equity
- The stock trades at a price-to-book ratio of 3.04 despite negative ROE of -1.27%, suggesting the valuation is not supported by current return generation
- Low interest coverage ratio indicates earnings are insufficient to comfortably service debt obligations, adding financial risk
- One-year stock CAGR of -26% reflects significant capital erosion for investors over the past twelve months
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: OneSource delivered a strong Q2FY27 with 37% revenue growth, 53% EBITDA growth, and dramatic margin expansion to 31.6%, prompting a 14% stock rally. Key risks include a potential Line 3 commercialization delay into early FY28 and a sharp rise in trade receivables due to geopolitical shipping disruptions. The $400m FY28 revenue target was reaffirmed and biologics traction is building with new US customer wins. The operational trend is clearly improving, but working capital stress and capacity timing slippage warrant monitoring over the next two quarters.
- Line 3 commercialization may slip Nov 03
Line 3 DDC capacity is installed but commercialization may slip to early FY28 due to lengthy qualification of bespoke European equipment, delaying revenue ramp.
- Trade receivables surge sharply Nov 03
Trade receivables surged to ₹10,329 million due to geopolitical shipping delays adding 45-60 days to collection cycle times, pressuring working capital.
- Stock still 29% below listing highs Oct 27
At ~₹1,598, the stock remains nearly 29% below its listing-era highs since its January 2025 listing, with no sustained directional trend yet.
- Q2 revenue up 37% YoY Oct 27
Q2FY27 revenue came in at ₹516.2 crore, up 37% YoY and 15% QoQ, marking the third consecutive quarter of sequential growth driven by new DDC capacity and 12 launches.
- Net profit jumps ~1,372% YoY Oct 27
Net profit surged to ₹93.7 crore from ₹6.37 crore a year ago, a ~1,372% YoY increase aided by operating leverage and margin expansion.
- EBITDA margin expands 300 bps Oct 27
EBITDA rose 53% YoY to ₹163.3 crore with margins expanding over 300 bps to 31.6%, reflecting improved operational efficiency.
- H2 ramp-up outlook shared Nov 03
Management indicated H2 will see new launches and significant commercial volume ramp-up from the second cartridge line, but this is forward guidance yet to be delivered.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34 | 56 | 73 | 292 | 334 | 393 | 426 | 327 | 376 | 290 | 428 | 449 |
| Expenses | 72 | 67 | 76 | 228 | 257 | 251 | 243 | 239 | 269 | 273 | 336 | 326 |
| Operating Profit | −39 | −10 | −3 | 64 | 77 | 142 | 183 | 88 | 106 | 17 | 92 | 123 |
| OPM % | −114% | −19% | −3.8% | 22% | 23% | 36% | 43% | 27% | 28% | 6% | 21% | 27% |
| Other Income | −32 | −74 | 3 | −1 | 0.58 | −94 | 2.89 | 2 | 3 | −2 | 2 | 0 |
| Interest | 25 | 26 | 20 | 42 | 45 | 46 | 33 | 27 | 34 | 38 | 23 | 31 |
| Depreciation | 18 | 20 | 20 | 68 | 68 | 69 | 68 | 68 | 70 | 70 | 72 | 72 |
| PBT | −114 | −130 | −40 | −47 | −37 | −67 | 83 | −4 | 6 | −93 | 0 | 20 |
| Tax % | 0% | 0% | 0% | −88% | 12% | 4% | −19% | −96% | −83% | −5% | −1630% | −23% |
| Net Profit | −114 | −130 | −40 | −6 | −42 | −69 | 98 | 0 | 10 | −89 | 5 | 25 |
| EPS (₹) | — | — | — | — | — | −6.02 | 8.61 | −0.02 | 0.92 | −7.74 | 0.4 | 2.18 |
Profit & Loss
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 21 | 132 | 39 | 172 | 1,445 | 1,422 | 1,543 |
| Expenses | 93 | 229 | 199 | 254 | 978 | 1,117 | 1,204 |
| Operating Profit | −71 | −97 | −161 | −82 | 467 | 304 | 339 |
| OPM % | −334% | −73% | −415% | −48% | 32% | 21% | 22% |
| Other Income | 1 | 4 | −526 | −143 | −94 | 5 | 2 |
| Interest | 16 | 68 | 48 | 89 | 166 | 122 | 126 |
| Depreciation | 34 | 70 | 66 | 76 | 274 | 279 | 283 |
| PBT | −121 | −231 | −800 | −391 | −67.07 | −92 | −67 |
| Tax % | 0% | 0% | 0% | 0% | −73% | −20% | — |
| Net Profit | −121 | −231 | −800 | −391 | −18 | −74 | −49 |
| EPS (₹) | — | — | — | — | −1.57 | −6.44 | −4.24 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 3 | 4 | 4 | 11 | 11 |
| Reserves | 774 | 1,009 | 781 | 392 | 5,869 | 5,820 |
| Borrowings | 386 | 1,154 | 864 | 562 | 772 | 1,276 |
| Other Liabilities | 96 | 276 | 365 | 468 | 1,005 | 1,197 |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,304 |
| Fixed Assets | 633 | 1,231 | 1,361 | 863 | 6,118 | 6,017 |
| CWIP | 431 | 490 | 334 | 188 | 218 | 529 |
| Investments | 0 | 0 | 4 | 20 | 16 | 16 |
| Other Assets | 195 | 722 | 314 | 356 | 1,305 | 1,742 |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,304 |
Cash Flow
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | −118 | −416 | −163 | −107 | −68 | 9 |
| Investing | −207 | −692 | −68 | 511 | −201 | −495 |
| Financing | 381 | 1,162 | 118 | −391 | 412 | 359 |
| Net Cash Flow | 56 | 54 | −112 | 13 | 143 | −127 |
| Free Cash Flow | −325 | −1,071 | −207 | −171 | −196 | −561 |
| CFO/EBITDA | 164 | 430 | 108 | 130 | −13 | 6 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 38 | 65 | 36 | 117 | 105 | 177 |
| Inventory Days | 87 | 1,805 | 615 | 258 | 222 | 438 |
| Days Payable | 762 | 410 | 420 | 163 | 147 | 307 |
| Cash Conversion Cycle | −637 | 1,461 | 232 | 212 | 180 | 308 |
| Working Capital Days | −2,392 | −1,291 | −6,745 | −877 | −58 | −6 |
| ROCE % | — | −10% | −12% | −12% | 6% | 1% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Onesource Specialty Pharma insights
62 extracted metrics across FY20–FY27.
Documents
- Q1 FY27 concall · Jul 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Jan 2026Transcript PPT Recording
- Q2 FY26 concall · Nov 2025Transcript PPT Recording
- Concall · Sep 2025PPT
- 17 Aug 2026
- 5 Mar 2026
- 3 Jun 2025
- 20 Feb 2025
- 23 Sep 2024
- General announcements 30 Oct 2026
- General announcements 27 Oct 2026
Frequently Asked Questions about Onesource Specialty Pharma
What does OneSource Specialty Pharma Ltd do?
Where is OneSource Specialty Pharma Ltd (ONESOURCE) listed?
Which sector does OneSource Specialty Pharma Ltd belong to?
What is the 52-week high and low of OneSource Specialty Pharma Ltd?
What is the Return on Equity (ROE) of OneSource Specialty Pharma Ltd?
Company Information
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ONESOURCE.md for OneSource Specialty Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.